Unia Europejska - polski - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis; microscopic polyangiitis; pemphigus - Środki przeciwnowotworowe - rixathon is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)rixathon is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. rixathon maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. rixathon monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. rixathon is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. rixathon in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chroniczna lymphocytic białaczka (cll)rixathon w połączeniu z chemioterapią wskazuje dla traktowania pacjenci z wcześniej nieleczonych i relapsed/opornym chroniczną lymphocytic. dostępne są tylko ograniczone dane dotyczące skuteczności i bezpieczeństwa dla pacjentów, wcześniej leczonych przeciwciała monoklonalne, w tym rytuksymab lub pacjentów, ogniotrwałe do poprzedniej rytuksymab + chemioterapia. cm. rozdział 5. 1 w celu uzyskania dalszych informacji. reumatoidalne arthritisrixathon w połączeniu z metotreksatem jest wskazany w leczeniu dorosłych pacjentów z ciężkim czynnym reumatoidalnym zapaleniem stawów, które miały niewystarczające odpowiedź lub nietolerancja innych choroba modyfikuje anty-reumatyczne leki (dmards przebieg), w tym jeden lub więcej czynnika martwicy nowotworu (tnf) inhibitor terapii. rytuksymab pokazywał, że zmniejsza szybkość postępu uszkodzenia stawów jak mierzy się promieniowanie x i ulepszać fizyczną funkcję, w momencie powołania, w połączeniu z metotreksatem. granulomatosis with polyangiitis and microscopic polyangiitisrixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). rixathon, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisrixathon is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Unia Europejska - polski - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - Środki przeciwnowotworowe - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. dostępne są tylko ograniczone dane dotyczące skuteczności i bezpieczeństwa dla pacjentów, wcześniej leczonych przeciwciała monoklonalne, w tym rytuksymab lub pacjentów, ogniotrwałe do poprzedniej rytuksymab + chemioterapia. cm. rozdział 5. 1 w celu uzyskania dalszych informacji. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rytuksymab pokazywał, że zmniejsza szybkość postępu uszkodzenia stawów jak mierzy się promieniowanie x i ulepszać fizyczną funkcję, w momencie powołania, w połączeniu z metotreksatem. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Unia Europejska - polski - EMA (European Medicines Agency)

teva b.v. - kwas zoledronowy - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - leki stosowane w leczeniu chorób kości - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. leczenie choroby pageta kości u dorosłych.

Unia Europejska - polski - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teryparatyd - osteoporosis; osteoporosis, postmenopausal - wapń homeostaza - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Unia Europejska - polski - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teryparatyd - osteoporosis; osteoporosis, postmenopausal - wapń homeostaza - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.